Alexander Staab

Good Practices in Model‐Informed Drug Discovery and Development: Practice, Application, and Documentation

SF Marshall, Rolf Burghaus, Valérie Cosson et al. · CPT Pharmacometrics & Systems Pharmacology · 2015 · 358 citations · Full text

Pharmacy, Pharmaceutical Policy, Drug Approval Processes +7

A Phase I Dose Escalation Study with Anti-CD44v6 Bivatuzumab Mertansine in Patients with Incurable Squamous Cell Carcinoma of the Head and Neck or Esophagus

Bernard M. Tijink, Jan Buter, Remco de Bree et al. · Clinical Cancer Research · 2006 · 316 citations · Full text

Pharmacy, Clinical Pharmacokinetics, Pharmacology +17

Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non‐valvular atrial fibrillation from the RE‐LY trial

Karl‐Heinz Liesenfeld, Thorsten Lehr, C. Dansirikul et al. · Journal of Thrombosis and Haemostasis · 2011 · 303 citations · Full text

Medicine, Cardiology, Pharmacokinetics +13

A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis

Michael W. Konstan, Gerd Döring, Sonya L. Heltshe et al. · Journal of Cystic Fibrosis · 2014 · 135 citations · Full text

Medicine, Pediatrics, Pharmacotherapy +13

Model‐Informed Drug Discovery and Development: Current Industry Good Practice and Regulatory Expectations and Future Perspectives

Scott Marshall, Rajanikanth Madabushi, Efthymios Manolis et al. · CPT Pharmacometrics & Systems Pharmacology · 2018 · 123 citations · Full text

Medicine, Pharmacology, Clinical Pharmacology +11